ADVFN - Advanced Financial Network.
HOME» NASDAQ » I » ISIS Stock Price » ISIS Stock News

Isis Pharmaceuticals Share News

 Isis Pharmaceuticals (mm) Stock Price
ISIS Stock Price
 Isis Pharmaceuticals (mm) Stock Chart
ISIS Stock Chart
 Isis Pharmaceuticals (mm) Stock News
ISIS Stock News
 Isis Pharmaceuticals (mm) Company Information
ISIS Company Information
 Isis Pharmaceuticals (mm) Stock Trades
ISIS Stock Trades

Sanofi: Strategic Partnership With Regulus Therapeutics

PARIS -(Dow Jones)- French pharmaceutical group Sanofi Aventis (SNY) and U.S.-basec company Regulus Inc. Tuesday said they entered into a global strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance will initially focus on the therapeutic area of fibrosis. MAIN FACTS: - MicroRNAs (micro-RiboNucleic Acid) are a new class of small non-coding RNAs that regulate gene expression by interfering with translation or stability of target messenger RNA transcripts. Endogenous microRNAs regulate the expression of over one-third of all human genes. The association of microRNA dysfunction with disease phenotypes has given rise to an entirely new class of pharmaceutically relevant targets. - Sanofi-Aventis and Regulus will collaborate on microRNA drug discovery and preclinical development for up to four microRNA targets, including the lead fibrosis program targeting microRNA-21. Sanofi-Aventis also received an option, which if exercised, provides access to the technology to develop and commercialize other micro-RNA based therapeutics, beyond the first four targets. - Regulus will receive a $25 million upfront fee and a future $10 million equity investment subject to mutual agreement on company valuation. The alliance could be valued at over $750 million when taking into account upfront payments, equity investment, research funding, and potential near-term preclinical, clinical and commercial milestone payments for multiple products. - Regulus was formed in 2007 and is jointly owned by Alnylam Pharmaceuticals and Isis Pharmaceuticals. - By Paris Bureau, Dow Jones Newswires; +331-4017-1740;

Stock News for Isis Pharmaceuticals (ISIS)
11/15/201518:00:11A Pro Forma Profit for ISIS Pharmaceuticals, Inc.
11/15/201515:00:03Alnylam Pharmaceuticals, Inc. Earnings: 100% Positive (Data)
11/12/201515:01:07Confidential Treatment Order (ct Order)
11/12/201507:42:03Pipeline Advancement Provides a Double-Digit Percentage Spark...
11/10/201507:00:00Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5...
11/09/201517:41:46Quarterly Report (10-q)
11/09/201517:10:30Securities Registration: Employee Benefit Plan (s-8)
11/09/201515:34:21Why Isis Pharmaceuticals Is More Potent Today
11/09/201507:16:10Current Report Filing (8-k)
11/09/201507:00:00Isis Reports Financial Results and Highlights for Third Quarter...
11/08/201510:30:00Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a...
11/06/201507:00:00Isis Pharmaceuticals to Present at Upcoming Investor Conferences
11/05/201507:00:00Isis Pharmaceuticals and Akcea Therapeutics Announce Start of...
11/04/201507:00:00Isis Pharmaceuticals to Host Webcast to Review ISIS-APO(a) Rx...
11/03/201506:00:00Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including...
10/30/201507:00:00Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in...
10/27/201521:12:40Isis Pharmaceuticals Gains 11% on News of a Phase 3 Development...
10/27/201507:00:00Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Rx Data...
10/26/201507:00:00ISIS Pharmaceuticals Earns $5 Million from GSK for Initiation...
10/23/201519:36:29Statement of Changes in Beneficial Ownership (4)

Isis Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations